Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's disease

45Citations
Citations of this article
51Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of extracellular amyloid-β peptide and intracellular tau. Here, we review data suggesting that prefibrillar tau oligomers mediate cognitive decline early in the disease. Objective: It was our aim to study the presence of tau-positive pretangle neurons and correlate findings with cognitive test scores. Methods: Pretangle antibodies (TOC1 and pS422) were applied to tissue containing cholinergic basal forebrain neurons from people who died with a premortem clinical diagnosis of no cognitive impairment, mild cognitive impairment and AD. Results: Data lend support to the concept that tau oligomers are the toxic form of tau, that non-fibillar tau relates to cognitive dysfunction and that the earliest pretangle pathology occurs in neuritic processes. Conclusions: Clinicopathological findings highlight the importance of studying tau modifications in neuronal soma and neuritic processes, which may be the earliest pathological lesions that correlate with cognitive status. © 2013 S. Karger AG, Basel.

Cite

CITATION STYLE

APA

Mufson, E. J., Ward, S., & Binder, L. (2014). Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer’s disease. Neurodegenerative Diseases, 13(2–3), 151–153. https://doi.org/10.1159/000353687

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free